Full-replicate design in two groups [General Sta­tis­tics]

posted by Mikalai  – Belarus, 2018-10-31 14:04  – Posting: # 19510
Views: 590

Dear all,
We are conducting a full replicate design study. Due to recruiting difficulties we had to split the study in two groups. It has been suggested that we should change our statistical model to model II of FDA. What risks, if any, carry on this model to our bioequivalence? Can additional factors in model artificially reduce our CV and push us out of the scaled approach to usual 125%-80% one (I am not a statistician, so my question may be statistically correct)? Should we change our usual 4-factor model?

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,404 posts in 4,122 threads, 1,323 registered users;
online 7 (1 registered, 6 guests [including 6 identified bots]).
Forum time (Europe/Vienna): 18:27 CEST

Those people who think they know everything
are a great annoyance to those of us who do.    Isaac Asimov

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5